Table 2.
Ex vivo effect of dasatinib on the expression of P-Selectin (CD62%) and the active form of fibrinogen receptor (%).
| CD62 |
Active fibrinogen receptor |
|||||
|---|---|---|---|---|---|---|
| Conditions | Control n = 7 | 3 h post Dasatinib n = 5 | 24 h post Dasatinib n = 5 | Control n = 7 | 3 h post Dasatinib n = 5 | 24 h post Dasatinib n = 5 |
| Apyrase 10 U mL−1 | ||||||
| Resting | 1.2 ± 1.1 | 0.4 ± 0.3 | 1.4 ± 1.0 | 0.4 ± 0.1 | 0.3 ± 0.1∗ | 0.2 ± 0.1∗ |
| U46619 1 μM | 9.0 ± 3.3 | 5.5 ± 6.7 | 17.3 ± 12.5 | 5.8 ± 3.4 | 2.0 ± 2.4∗ | 10.3 ± 9.4 |
| U46619 50 nM | 1.9 ± 1.6 | 0.4 ± 0.4 | 4.5 ± 4.7∗ | 0.6 ± 0.2 | 0.2 ± 0.1∗ | 1.1 ± 1.7 |
| Epinephrine 10 μM | 6.7 ± 3.9 | 1.3 ± 1.7∗† | 8.4 ± 4.3∗ | 3.3 ± 2.4 | 0.4 ± 0.4∗ | 3.9 ± 3.1∗ |
| U46619 50 nM + epinephrine 10 μM | 24.5 ± 16.6 | 7.4 ± 9.4 | 24.5 ± 23.1 | 14.3 ± 11.1 | 1.8 ± 2.3∗ | 15.8 ± 16.0 |
| U46619 1 μM + eptifibatide 10 μg mL−1 | 22.7 ± 10.9 | 11.6 ± 11.8 | 28.0 ± 17.4 | 0.4 ± 0.2 | 0.6 ± 0.8 | 0.2 ± 0.1∗ |
| ADP 5 μM | 2.2 ± 1.6 | 0.9 ± 0.9† | 2.7 ± 1.3 | 0.5 ± 0.1 | 0.2 ± 0.1† | 0.5 ± 0.4 |
| Collagen 10 μg mL−1 | 2.4 ± 0.9 | 1.6 ± 1.3 | 2.9 ± 0.8 | 1.5 ± 0.5 | 1.3 ± 0.6 | 1.5 ± 0.6 |
| Collagen 10 μg mL−1 + U46619 50 nM | 3.9 ± 0.9 | 2.5 ± 1.6 | 4.7 ± 2.8 | 6.0 ± 9.6 | 1.5 ± 0.6 | 3.0 ± 1.7 |
| Without apyrase | ||||||
| Resting | 1.7 ± 1.4 | 0.2 ± 0.1∗ | 1.7 ± 1.4 | 0.4 ± 0.2 | 0.2 ± 0.1 | 0.2 ± 0.1 |
| U46619 1 μM | 31.5 ± 19.2 | 11.0 ± 12.4† | 39.2 ± 31.4 | 29.7 ± 24.7 | 3.9 ± 5.0∗† | 33.6 ± 27.7 |
| U46619 50 nM | 2.5 ± 1.5 | 0.4 ± 0.2∗† | 6.36 ± 7.7∗ | 0.8 ± 0.5 | 0.2 ± 0.1∗ | 2.6 ± 3.9 |
| Epinephrine 10 μM | 8.2 ± 3.6 | 1.2 ± 1.4∗† | 10.5 ± 5.8 | 6.6 ± 3.9 | 0.6 ± 0.6∗† | 7.9 ± 5.9 |
| U46619 50 nM + epinephrine 10 μM | 32.2 ± 20.8 | 9.2 ± 11.4† | 32.0 ± 25.6 | 24.4 ± 15.7 | 2.5 ± 3.1∗† | 27.3 ± 25.3 |
| U46619 1 μM + eptifibatide 10 μg mL−1 | 64.2 ± 16.7 | 24.4 ± 26.5∗† | 47.6 ± 34.9∗ | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.1 ± 0.1 |
| ADP 5 μM | 40.5 ± 8.1 | 21.1 ± 20.9† | 41.4 ± 18.1 | 49.7 ± 16.7 | 20.5 ± 19.4∗† | 46.7 ± 25.5 |
| Collagen 10 μg mL−1 | 2.6 ± 0.9 | 1.5 ± 0.9† | 3.4 ± 1.0 | 1.6 ± 0.6 | 1.3 ± 0.5 | 1.8 ± 0.7 |
| Collagen 10 μg mL−1 + U46619 50 nM | 4.1 ± 0.6 | 2.3 ± 1.2∗† | 4.6 ± 2.9 | 2.7 ± 1.1 | 1.5 ± 0.4† | 3.6 ± 1.6 |
Mean ± SD, ∗P < 0.05: vs. control, †P < 0.05 3 h post dasatinib vs. 24 h post dasatinib. PRP was prepared in the presence of ASA 100 μM with and without apyrase VII 10 U mL–1 from healthy volunteers or patients, 3 and 24 h post treatment with dasatinib, in the presence or absence of eptifibatide 10 μg mL–1. Data are expressed as % of positive events. One-way ANOVA, followed by Newman–Keuls as post hoc test was applied to compare each agonist in the presence or absence of dasatinib with resting conditions in patients and controls. Active fibrinogen receptor and CD62 were separately analyzed.